Induction of protective immunity against H1N1 influenza A(H1N1)pdm09 with spray-dried and electron-beam sterilised vaccines in non-human primates

Vaccine

Volumn 32, Issue 19, 2014, Pages 2231-2240

  Scherließ, Regina ^a   Ajmera, Ankur ^a   Dennis, Mike ^b   Carroll, Miles W ^b   Altrichter, Jens ^c   Silman, Nigel J ^b   Scholz, Martin ^c   Kemter, Kristina ^c   Marriott, Anthony C ^b  

^a UNIVERSITY OF KIEL   (Germany)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

^c LEUKOCARE AG   (Germany)

Author keywords

Dry powder vaccine; Excipients; Irradiation; Stabilising and protecting solution (SPS); Thermal stability; Viruses

Indexed keywords

AMINO ACID; CHITOSAN; EXCIPIENT; GLYCYRRHIZIC ACID; INFLUENZA VACCINE; MANNITOL; TREHALOSE;

AEROSOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASSAY; CONTROLLED STUDY; DRUG FORMULATION; DRUG SAFETY; DRUG STABILITY; DRUG STERILITY; DRUG STORAGE; DRY POWDER; ELECTRON BEAM; FEMALE; GEL PERMEATION CHROMATOGRAPHY; HEMAGGLUTINATION INHIBITION; IN VITRO STUDY; IN VIVO STUDY; INFLUENZA A (H1N1); INFLUENZA VACCINATION; IRRADIATION; LIGHT SCATTERING; MALE; NEEDLE FREE VACCINATION; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIMATE; PRIORITY JOURNAL; SEROCONVERSION; THERMOSTABILITY;

DRY POWDER VACCINE; EXCIPIENTS; IRRADIATION; STABILISING AND PROTECTING SOLUTION (SPS); THERMAL STABILITY; VIRUSES;

ANIMALS; DESICCATION; DRUG STORAGE; EXCIPIENTS; FEMALE; GLYCYRRHIZIC ACID; HEMAGGLUTINATION INHIBITION TESTS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; MACACA FASCICULARIS; MALE; MANNITOL; NEUTRALIZATION TESTS; ORTHOMYXOVIRIDAE INFECTIONS; POWDERS; STERILIZATION; TREHALOSE; VACCINE POTENCY;

EID: 84897109251     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.01.077     Document Type: Article

References (53)

1. Scherließ R. Delivery of antigens used for vaccination - recent advances and challenges. Ther Deliv 2011, 2(10):1351-1368.
2. WHO GIVS: global immunization vision and strategy 2005, WHO, Geneva.
3. Amorij J.-P., Huckriede A., Wilschut J., Frijlink H.W., Hinrichs W.L.J. Development of stable influenza vaccine powder formulations: challenges and possibilities. Pharm Res 2008, 25(6):1256-1273.
4. Hasija M., Li L., Rahman N., Ausar S.F. Forced degradation studies: an essential tool for the formulation development of vaccines. Vaccine Dev Ther 2013, 3:11-33.
5. Brandau D.T., Jones L.S., Wiethoff C.M., Rexroad J., Middaugh C.R. Thermal stability of vaccines. J Pharm Sci 2003, 92(2):218-231.
6. Taneja S., Ahmad F. Increased thermal stability of proteins in the presence of amino acids. Biochem J 1994, 303:147-153.
7. Wang W. Lyophilization and development of solid protein pharmaceuticals. Int J Pharm 2000, 203:1-60.
8. Amorij J.-P., Meulenaar J., Hinrichs W.L.J., Stegmann T., Huckriede A., Coenen F., et al. Rational design of an influenza subunit vaccine powder with sugar glass technology: preventing conformational changes of haemagglutinin during freezing and freeze-drying. Vaccine 2007, 25:6447-6457.
9. Vehring R. Pharmaceutical particle engineering via spray drying. Pharm Res 2008, 25:999-1022.
10. Maury M., Murphy K., Kumar S., Mauerer A., Lee G. Spray-drying of proteins: effects of sorbitol and trehalose on aggregation and FT-IR amide I spectrum of an immunoglobulin. G. EJPB 2005, 59:251-261.
11. Elkordy A.A., Forbes R.T., Barry B.W. Stability of crystallised and spray-dried lysozyme. Int J Pharm 2004, 278(2):209-219.
12. Saluja V., Amorij J.-P., Kapteyn J.C., de Boer A.H., Frijlink H.W., Hinrichs W.L.J. A comparison between spray drying and spray freeze drying to produce an influenza subunit vaccine powder for inhalation. J Controlled Release 2010, 144:127-133.
13. Abdul-Fattah A.M., Truong-Le V., Yee L., Pan E., Ao Y., Kalonia D.S., et al. Drying-induced variations in physico-chemical properties of amorphous pharmaceuticals and their impact on stability II: stability of a vaccine. Pharm Res 2007, 24(4):715-727.
14. Lal M. Technologies for the development of thermostable vaccines. PATH 2013.
15. Son Y.-J., McConville J.T. Development of a standardized dissolution test for inhalable formulations. Respiratory drug delivery 2008, DHI, Scottsdale, Arizona, USA, p. 927-30.
16. Rathore N., Rajan R.S. Current perspectives on stability of drug products during formulation, fill and finish operations. Biotechnol Prog 2008, 24:504-514.
17. Shire S.J. Formulation and manufacturability of biologics. Curr Opin Biotechnol 2009, 20:708-714.
18. Bhamra K., Harrison P., Philipps J., Hale G. Aseptic vial filling. Methods Mol Med 2000, 40:313-317.
19. Zbikowska H.M., Nowak P., Wachowicz B. Protein modification caused by a high dose of gamma irradiation in cryo-sterilized plasma: protective effects of ascorbate. Free Radical Biol Med 2006, 40:536-542.
20. Garrison W.M., Jayko M.E., Bennett W. Radiation-induced oxidation of protein in aqueous solution. Radiat Res 1962, 16:483-502.
21. Kapoor S., Priyadarisini K.I. Protection of radiation-induced protein damage by curcumin. Biophys Chem 2001, 92:119-126.
22. De Groot A.S., Scott D.W. Immunogenicity of protein therapeutics. Trends Immunol 2007, 28(11):482-490.
23. Scholz M., Altenhofen W. Stabilising biologics for vaccine production. Manufacturing Chemist Pharma 2001, 9:32-34.
24. Scholz M., Lüking A. A protein-stabilizing technology for enhanced antibody stability and antibody-binding profiles in a microchip array. Biotechnol J 2012, 7:1002-1007.
25. Tscheliessnig R., Zörnig M., Herzig E.M., Lückerath K., Altrichter J., Kemter K., et al. Nano-coating protects biofunctional materials. Mater Today 2012, 15(9):394-404.
26. Garcia-Cañas V., Lorbetskie B., Cyr T.D., Hefford M.A., Smith S., Girard M. Approach to the profiling and characterization of influenza vaccine constituents by the combined use of size-exclusion chromatography, gel electrophoresis and mass-spectroscopy. Biologicals 2010, 38(2):294-302.
27. Ajmera A., Scherließ R. Dry powder formulation of proteins via spray drying. 8th World meeting on pharmaceutics, biopharmaceutics and pharmaceutical technology 2012.
28. Scherließ R., Buske S., Young K., Weber B., Rades T., Hook S. In vivo evaluation of chitosan as an adjuvant in subcutaneous vaccine formulations. Vaccine 2013, 31:4812-4819.
29. Sun H.-X., Yong X., Ye Y.-P. Advances in saponin-based adjuvants. Vaccine 2009, 27:1787-1796.
30. Dai J.H., Iwatani Y., Ishida T., Terunuma H., Kasai H., Iwakula Y., et al. Glycyrrhizin enhances interleukin-12 production in peritoneal macrophages. Immunology 2001, 103(2):235-243.
31. Li C., Shao M., Cui X., Song Y., Li J., Yuan L., et al. Application of deglycosylation and electrophoresis to the quantification of influenza viral haemagglutinins facilitating the production of 2009 pandemic influenza (H1N1) vaccines at multiple manufacturing sites in china. Biologics 2010, 1-6.
32. Wydro P., Krajewska B., Hac-Wydro K. Chitosan as a lipid binder: a langmuir monolayer study of chitosan-lipid interactions. Biomacromolecules 2007, 8:2611-2617.
33. Maa Y.-F., Ameri M., Shu C., Payne L.G., Chen D. Influenza vaccine powder formulation development: spray-freeze-drying and stability evaluation. J Pharm Sci 2004, 93(7):1912-1923.
34. Maas S.G., Schaldach G., Littringer E.M., Mescher A., Griesser U.J., Braun D.E., et al. The impact of spray drying outlet temperature on the particle morphology of mannitol. Powder Tech 2011, 213:27-35.
35. Wakankar A.A., Borchardt R.T. Formulation considerations for proteins susceptible to asparagine deamidation and aspartate isomerization. J Pharm Sci 2006, 95:2321-2336.
36. Han Y., Jin B.S., Lee S.B., Sohn Y., Joung J.W., Lee J.H. Effects of sugar additives on protein stability of recombinant human serum albumin during lyophilization and storage. Arch Pharm Res 2007, 30(9):1124-1131.
37. Shimizu S.D.J.S. Preferential hydration and the exclusion of cosolvents from protein surfaces. J Chem Phys 2004, 121:1148-1154.
38. Auton M., Bolen D.W., Rosgen J. Structural thermodynamics of protein preferential solvation: osmolyte solvation of proteins, amino acids, and peptides. Proteins 2008, 73:802-813.
39. Aspden T.J., Masen J.T.D., Jones N.S., Lowe J., Skaugrud Ö, Illum L. Chitosan as a nasal delivery system: the effect of chitosan solutions on in vitro and in vivo mucociliary transport rates in human turbinates and volunteers. J Pharm Sci 1997, 86(4):509-513.
40. Davis S.S., Illum L. Absorption enhancers for nasal drug delivery. Clin Pharmacokinet 2003, 42(13):1107-1128.
41. Illum L., Farraj N.F., Davis S.S. Chitosan as a novel nasal delivery system for peptide drugs. Pharm Res 1994, 11(8):1186-1189.
42. Illum L., Jabbal-Gill I., Hinchcliffe M., Fisher A.N., Davis S.S. Chitosan as a novel nasal delivery system for vaccines. Adv Drug Deliv Rev 2001, 51:81-96.
43. Delafuente J.C., Davis J.A., Meuleman J.R., Ronald Jones A. Influenza vaccination and warfarin anticoagulation: a comparison of subcutaneous and intramuscular routes of administration in elderly men. Pharmacotherapy 1998, 18(3):631-636.
44. Huang J., Garmise R.J., Crowder T.M., Mar K., Hwang C.R., Hickey A.J., et al. A novel dry powder influenza vaccine and intranasal delivery technology: induction of systemic and mucosal immune responses in rats. Vaccine 2004, 23:794-801.
45. Hashigucci K., Ogawa H., Ishidate T., Yamashita R., Kamiya H., Watanabe K., et al. Antibody responses in volunteers induced by nasal influenza vaccine combined with Escherichia coli heat-labile enterotoxin B subunit containing a trace amount of the holotoxin. Vaccine 1996, 14(2):113-119.
46. Muszkat M., Ben Yehuda A., Schein M.H., Friedlander Y., Naveh P., Greenbaum E., et al. Local and systemic immune response in community-dwelling elderly after intranasal or intramuscular immunization with inactivated influenza vaccine. J Med Virol 2000, 61:100-106.
47. Moldoveanu Z., Clements M.L., Prince S.J., Murphy B.R., Mestecky J. Human immune responses to influenza virus vaccine administered by mucosal or systemic routes. Vaccine 1995, 11:1006-1012.
48. Smith D.J., Bot S., Dellamary L., Bot A. Evaluation of novel aerosol formulations designed for mucosal vaccination against influenza virus. Vaccine 2003, 21:2805-2812.
49. Belshe R.B., Edwards K.M., Vesikari T., Black S.V., Walker R.E., Hultquist M., et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 2007, 356:685-696.
50. Anderson J., Fishbourne E., Corteyn A., Donaldson A.I. Protection of cattle against rinderpest by intranasal immunisation with a dry powder tissue culture vaccine. Vaccine 2001, 19(7-8):840-843.
51. LiCalsi C., Christensen T., Bennett J.V., Philipps E., Witham C. Dry powder inhalation as a potential delivery method for vaccines. Vaccine 1999, 17(13-14):1796-1803.
52. Heyder J. Deposition of inhaled particles in the human respiratory tract and consequences for regional targeting in respiratory drug delivery. Proc Am Thrac Soc 2004, 1:315-320.
53. Frijlink H.W., DeBoer A.H. Dry powder inhalers for pulmonary drug delivery. Expert Opin Drug Deliv 2004, 1:67-86.